News

GeoVax to Participate in BIO International Convention 2025
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and ...
GeoVax Highlights Broad Cross-Protective Immunity of Multi-Antigen COVID-19 Vaccine Candidates at Keystone Symposia
Preclinical Studies Demonstrate Durable Protection Against SARS-CoV-2 Variants, Including Omicron XBB.1.5, Driven by T-Cell Responses  ATLANTA, GA - June 9, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc.
GeoVax Responds to WHO's Fourth Declaration of Mpox as a Global Public Health Emergency
GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today issued a statement in response to the World Health Organization’s ...
Yahoo Finance3d
GeoVax Responds to WHO's Fourth Declaration of Mpox as a Global Public Health Emergency
ATLANTA, GA - June 11, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today issued a ...
Seeking Alpha1d
GOVX GeoVax Labs, Inc.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the ...
Seeking Alpha3d
GOVXW GeoVax Labs, Inc. WT EXP 092925
GeoVax Labs, Inc. WT EXP 092925 SEC Filing - Annual Report (10-K) March 27, 2025 SEC Filings Thu, Mar. 27 GeoVax Labs, Inc. (GOVX) Q3 2024 Earnings Call Transcript ...